Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2025)

Historic Other Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 2 years, with Q3 2025 value amounting to $2.9 million.

  • Crinetics Pharmaceuticals' Other Non-Current Liabilities rose 46634.05% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 46634.05%. This contributed to the annual value of $829000.0 for FY2024, which is N/A changed from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $2.9 million for Q3 2025, which was up 46634.05% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $2.9 million in Q3 2025 and a low of $202000.0 during Q2 2024